Mark Sausen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10270990/publications.pdf

Version: 2024-02-01

29 papers	9,513 citations	304701 22 h-index	501174 28 g-index
29 all docs	29 docs citations	29 times ranked	16146 citing authors

#	Article	IF	Citations
1	Homologous Recombination Deficiency: Concepts, Definitions, and Assays. Oncologist, 2022, 27, 167-174.	3.7	69
2	Automated next-generation profiling of genomic alterations in human cancers. Nature Communications, 2022, 13, .	12.8	8
3	Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade. Clinical Cancer Research, 2019, 25, 7024-7034.	7.0	104
4	A machine learning approach for somatic mutation discovery. Science Translational Medicine, 2018, 10, .	12.4	80
5	Whole-Exome Sequencing of Salivary Gland Mucoepidermoid Carcinoma. Clinical Cancer Research, 2017, 23, 283-288.	7.0	70
6	Clinical study of genomic drivers in pancreatic ductal adenocarcinoma. British Journal of Cancer, 2017, 117, 572-582.	6.4	26
7	Direct detection of early-stage cancers using circulating tumor DNA. Science Translational Medicine, 2017, 9, .	12.4	808
8	The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA. Clinical Cancer Research, 2017, 23, 2471-2477.	7.0	154
9	Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors. Molecular Cancer Therapeutics, 2016, 15, 1746-1756.	4.1	45
10	Whole-Genome Sequencing of Salivary Gland Adenoid Cystic Carcinoma. Cancer Prevention Research, 2016, 9, 265-274.	1.5	80
11	Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nature Communications, 2015, 6, 7686.	12.8	393
12	Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Science Translational Medicine, 2015, 7, 293ra104.	12.4	372
13	Personalized genomic analyses for cancer mutation discovery and interpretation. Science Translational Medicine, 2015, 7, 283ra53.	12.4	347
14	The genomic landscape of response to EGFR blockade in colorectal cancer. Nature, 2015, 526, 263-267.	27.8	398
15	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Science Translational Medicine, 2014, 6, 224ra24.	12.4	3,665
16	Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. , 2014, 2, 42.		186
17	Circulating tumor DNA moves further into the spotlight. Genome Medicine, 2014, 6, 35.	8.2	23
18	Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes. Nature Communications, 2014, 5, 5006.	12.8	149

#	Article	IF	Citations
19	Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nature Genetics, 2014, 46, 1170-1172.	21.4	247
20	Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nature Genetics, 2013, 45, 12-17.	21.4	374
21	Exomic Sequencing of Medullary Thyroid Cancer Reveals Dominant and Mutually Exclusive Oncogenic Mutations in RET and RAS. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E364-E369.	3.6	213
22	Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. Cancer Discovery, 2013, 3, 658-673.	9.4	585
23	Cancer detection using whole-genome sequencing of cell free DNA. Oncotarget, 2013, 4, 1119-1120.	1.8	11
24	Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNA. Oncotarget, 2013, 4, 1856-1857.	1.8	39
25	Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing. Science Translational Medicine, 2012, 4, 162ra154.	12.4	557
26	Identification of a HMGA2-EFCAB6 gene rearrangement following next-generation sequencing in a patient with a t(12;22)(q14.3;q13.2) and JAK2V617F-positive myeloproliferative neoplasm. Cancer Genetics, 2012, 205, 295-303.	0.4	10
27	Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma. Science, 2011, 333, 1453-1455.	12.6	485
28	Chronic myeloid leukemia with e19a2 atypical transcript: early imatinib resistance and complete response to dasatinib. Cancer Genetics and Cytogenetics, 2010, 201, 133-134.	1.0	11
29	BRCA1 E1644X: a deleterious mutation in an African American individual with early onset breast cancer. Breast Cancer Research and Treatment, 2009, 113, 393-395.	2.5	4